Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Andréia C. de Melo"'
Autor:
Juliana L. Souza, Karina Martins-Cardoso, Isabella S. Guimarães, Andréia C. de Melo, Angela H. Lopes, Robson Q. Monteiro, Vitor H. Almeida
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase widely expressed in cervical tumors, being correlated with adverse clinical outcomes. EGFR may be activated by a diversity of mechanisms, including transactivation by G-protein cou
Externí odkaz:
https://doaj.org/article/9d1afa614c9e44bc82930f3dbfc63e8a
Autor:
Juliana, Ominelli, Rodrigo O de Castro, Araujo, Marcus, Valadão, Monica L A, Padoan, Victor M, Lopes Dos Santos, Jamille G, Dutra, Claudia C, Torres, Monique A, Barbosa, Raquel, Guimarães, Juliana C Carneiro, Carvalho, Maria A, Ferreira, Ivanir M, de Oliveira, Isabele, Small, Andréia C, de Melo, Luiz H, Araujo
Publikováno v:
Clinical Colorectal Cancer. 21:e196-e204
INDUCTION: chemotherapy (IC) followed by chemoradiation (CRT) is an attractive approach in high-risk locally advanced rectal cancer. Additionally, ASA has shown potential to improve outcomes alongside CRT in rectal cancer. The ICAR trial aimed to eva
Autor:
Nicoletta Colombo, Robert L Coleman, Xiaohua Wu, Fatih Köse, Robert M Wenham, Alexandra Sebastianelli, Kosei Hasegawa, Emese Zsiros, Thibault De La Motte Rouge, Mariusz Bidziński, Iain McNeish, Jalid Sehouli, Jacob Korach, Philip R Debruyne, Jae-Weon Kim, Andréia C de Melo, Xuan Peng, Agata M Bogusz, Karin Yamada, Bradley J Monk
Publikováno v:
Ovarian cancer.
Autor:
Nicoletta Colombo, Robert L. Coleman, Xiaohua Wu, Fatih Köse, Robert Michael Wenham, Alexandra Sebastianelli, Kosei Hasegawa, Emese Zsiros, Thibault De La Motte Rouge, Mariusz Bidziński, Iain A. McNeish, Jalid Sehouli, Jacob Korach, Philip R. Debruyne, Jae-Weon Kim, Andréia C. de Melo, Xuan Peng, Agata M. Bogusz, Karin Sayuri Yamada, Bradley J. Monk
Publikováno v:
Journal of Clinical Oncology. 40:TPS5617-TPS5617
TPS5617 Background: Despite therapeutic advances in ovarian cancer, platinum-resistant recurrent ovarian cancer (PROC) remains an area of high unmet clinical need and there is an urgent need for new treatments to further improve clinical outcomes. Ad
Autor:
Aline B. Lara Gongora, Gustavo Werutsky, Denis L. Jardim, Angelica Nogueira-Rodrigues, Carlos H. Barrios, Clarissa Mathias, Fernando Maluf, Rachel Riechelmann, Maurício Fraga, Henry Gomes, William N. William, Camilla A. F. Yamada, Gilberto de Castro Jr, Daniela D. Rosa, Andreia C. de Melo, Raul Sala, Eva Bustamante, Denisse Bretel, Oscar Arrieta, Andrés F. Cardona, Diogo A. Bastos
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 649-658 (2021)
PURPOSECOVID-19 has affected cancer care worldwide. Clinical trials are an important alternative for the treatment of oncologic patients, especially in Latin America, where trials can be the only opportunity for some of them to access novel and, some
Externí odkaz:
https://doaj.org/article/c6436c3390d04fb48eb100f0ab3f6c2c